Solid Biosciences Total Assets Growth & History (SLDB)
Solid Biosciences's total assets was $232.5M for fiscal 2025.
View full Solid Biosciences company overviewSolid Biosciences annual total assets history
| Fiscal year | Period ended | Total assets | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $232.5M | $43.9M | +23.26% |
| 2024 | 2024-12-31 | $188.7M | $23.7M | +14.38% |
| 2023 | 2023-12-31 | $164.9M | −$95.3M | −36.62% |
| 2022 | 2022-12-31 | $260.3M | $27.9M | +11.99% |
| 2021 | 2021-12-31 | $232.4M | $61.2M | +35.76% |
| 2020 | 2020-12-31 | $171.2M | $67.7M | +65.43% |
| 2019 | 2019-12-31 | $103.5M | −$36.1M | −25.88% |
| 2018 | 2018-12-31 | $139.6M | $63.4M | +83.21% |
| 2017 | 2017-12-31 | $76.2M | — | — |
Solid Biosciences quarterly total assets
| Fiscal quarter | Period ended | Total assets | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $420.6M | $112.3M | +36.42% |
| Q1 2026 | 2026-03-31 | $422.9M | $79.0M | +22.97% |
| Q4 2025 | 2025-12-31 | $232.5M | $43.9M | +23.26% |
| Q3 2025 | 2025-09-30 | $273.9M | $62.1M | +29.31% |
| Q2 2025 | 2025-06-30 | $308.3M | $77.3M | +33.47% |
| Q1 2025 | 2025-03-31 | $343.9M | $95.2M | +38.29% |
| Q4 2024 | 2024-12-31 | $188.7M | $23.7M | +14.38% |
| Q3 2024 | 2024-09-30 | $211.8M | $27.1M | +14.67% |
| Q2 2024 | 2024-06-30 | $231.0M | $26.3M | +12.83% |
| Q1 2024 | 2024-03-31 | $248.7M | $19.1M | +8.32% |
| Q4 2023 | 2023-12-31 | $164.9M | −$95.3M | −36.62% |
| Q3 2023 | 2023-09-30 | $184.7M | $254,000 | +0.14% |
| Q2 2023 | 2023-06-30 | $204.7M | −$3.8M | −1.81% |
| Q1 2023 | 2023-03-31 | $229.6M | $22.0M | +10.61% |
| Q4 2022 | 2022-12-31 | $260.3M | $27.9M | +11.99% |
| Q3 2022 | 2022-09-30 | $184.5M | −$64.5M | −25.91% |
| Q2 2022 | 2022-06-30 | $208.5M | −$57.4M | −21.58% |
| Q1 2022 | 2022-03-31 | $207.6M | −$77.7M | −27.24% |
| Q4 2021 | 2021-12-31 | $232.4M | $61.2M | +35.76% |
| Q3 2021 | 2021-09-30 | $249.0M | $208.5M | +514.51% |
| Q2 2021 | 2021-06-30 | $265.9M | $207.9M | +358.67% |
| Q1 2021 | 2021-03-31 | $285.3M | $211.3M | +285.72% |
| Q4 2020 | 2020-12-31 | $171.2M | $67.7M | +65.43% |
| Q3 2020 | 2020-09-30 | $40.5M | −$90.4M | −69.05% |
| Q2 2020 | 2020-06-30 | $58.0M | −$38.3M | −39.81% |
| Q1 2020 | 2020-03-31 | $74.0M | −$46.3M | −38.49% |
| Q4 2019 | 2019-12-31 | $103.5M | −$36.1M | −25.88% |
| Q3 2019 | 2019-09-30 | $130.9M | −$25.9M | −16.51% |
| Q2 2019 | 2019-06-30 | $96.3M | −$75.2M | −43.84% |
| Q1 2019 | 2019-03-31 | $120.2M | −$69.0M | −36.47% |
| Q4 2018 | 2018-12-31 | $139.6M | $63.4M | +83.21% |
| Q3 2018 | 2018-09-30 | $156.8M | — | — |
| Q2 2018 | 2018-06-30 | $171.5M | — | — |
| Q1 2018 | 2018-03-31 | $189.2M | — | — |
| Q4 2017 | 2017-12-31 | $76.2M | — | — |
Solid Biosciences total assets trends
Over the last five fiscal years, Solid Biosciences's total assets increased from $171.2M to $232.5M, a change of $61.4M. The latest reported quarter, Q2 2026, shows $420.6M.
What total assets mean
Total assets are the resources a company controls at a reporting-period end, including cash, investments, receivables, inventory, property, intangible assets, and other reported assets. The composition of assets differs substantially by industry.
SEC-reported total assets
TickerStat uses total assets reported in company SEC filings. When a filer provides the equivalent balance-sheet total as liabilities and equity, that reported amount is used because total assets must equal total liabilities plus equity. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Solid Biosciences source filings ↗